{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2019"],"data_sharing_plan":["IPD Sharing (as of February 2022): No"],"condition":["Ovarian Cancer","Leukemia, Myeloid","Triple Negative Breast Neoplasms","Colorectal Cancer","Small Cell Lung Carcinoma","Triple-negative Breast Cancer","Small-cell Lung Cancer","Leukemia, Myeloid, Acute","Acute Myelogenous Leukemia"],"disease":["Ovarian Cancer","Leukemia, Myeloid","Triple Negative Breast Neoplasms","Colorectal Cancer","Small Cell Lung Carcinoma","Triple-negative Breast Cancer","Small-cell Lung Cancer","Leukemia, Myeloid, Acute","Acute Myelogenous Leukemia"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2291112"],"location":["United States"],"study_start_month":["6"],"keyword":["Checkpoint inhibitor","SLS-001","Combination immunotherapy","Off-the-shelf vaccine","Peptide vaccine","Immuno-oncology","WT1-expressing tumors","Pembrolizumab","PD1 inhibitor","Galinpepimut-S","Multivalent","HLA allele","Heteroclitic","WT1 analog peptide vaccine","WT1 vaccine"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","description":"To evaluate the safety and tolerability of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers. Patients will be followed long-term for Overall Survival (OS) and safety. The study will enroll approximately 90 patients and maximum study treatment duration is approximately 2.13 years.","dates":{"creation":"2019-06-15"},"accession":"2291112","cross_references":{"ClinicalTrials___gov":["NCT03761914"]}}